Tetra Therapeutics
38 Fulton St W Ste 303
Grand Rapids
Michigan
49503
United States
Website: https://tetratherapeutics.com/
28 articles about Tetra Therapeutics
-
Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome
7/12/2022
Tetra Therapeutics, a Shionogi Group Company, focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, today announced the initiation of three Phase 2b/3 clinical studies of the investigational drug BPN14770 (zatolmilast) as a potential treatment for Fragile X Syndrome (FXS), the most common genetic form of autism.
-
Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession
7/23/2021
Tetra Therapeutics announced changes to its executive team as the company marks one year since the close of its merger with Shionogi & Co., Ltd..
-
An investigational Alzheimer's disease drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.
-
Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome
11/2/2020
Study shows significant cognitive improvement in domains related to language and caregivers reported improved language and daily functioning Lead drug candidate continues to be safe and well-tolerated
-
Tetra Therapeutics Enters Into Definitive Merger Agreement To Be Acquired by Shionogi
5/26/2020
Tetra Therapeutics today announced that it has entered into a definitive merger agreement for Shionogi & Co., Ltd. to acquire Tetra. With this acquisition, Shionogi will obtain global rights to Tetra’s entire portfolio of compounds for
-
Tetra Therapeutics and Shionogi Announce Expanded Alliance
3/6/2020
Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced it has entered into an expanded strategic alliance with Shionogi
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
Tetra Therapeutics Announces Presentation of Data from Retrospective Population-Based Study of 56 Million Patients at the 12th Clinical Trials on Alzheimer’s Disease Meeting (CTAD)
12/4/2019
Study Shows that TNF Blocking Agents Reduce Risk of Alzheimer’s Disease in Patients with Rheumatoid Arthritis or Psoriasis
-
Tetra Therapeutics Sees Rapid Patient Recruitment and Representative Patient Diversity in its PICASSO Phase 2 Alzheimer’s Disease Trial
9/19/2019
Just ahead of World Alzheimer’s Day on September 21st, Tetra Therapeutics, a clinical-stage biotechnology company, today announced it has surpassed 50% enrollment – 65% of which are Hispanic patients– in its Phase 2 clinical trial (PICASSO AD) of BPN14770 in patients diagnosed with early Alzheimer’s disease (AD), since the trial’s initiation in May.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Tetra Discovery Partners Announces Name Change to Tetra Therapeutics
8/5/2019
Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the company’s name change to Tetra Therapeutics
-
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization
12/18/2018
Deal Valued at Potential $160 Million plus Royalties, including $5 Million in Upfront Payments and $35 Million in Equity Investment
-
Intellectual Property Protection for Tetra Discovery Partners’ BPN14770 Boosted with Issuance of New U.S. Patent
10/11/2018
The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia.
-
Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome
7/10/2018
Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome
-
Tetra’s fragile X syndrome drug must demonstrate significant therapeutic benefits to secure market share, says GlobalData
5/4/2018
BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the FDA in April 2018.
-
FDA Grants Orphan Drug Designation for Tetra Discovery Partners’ BPN14770 for the Treatment of Fragile X Syndrome
4/3/2018
BPN14770 is a selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype.
-
Tetra Discovery Partners announced that the FDA had given its Investigational New Drug application the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders.
-
Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome
3/15/2018
Tetra Discovery Partners Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application (IND) for BPN14770.
-
New Preclinical Research Suggests Utility of Tetra Discovery Partners' BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome
11/7/2017
Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology.
-
Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition
11/6/2017
BPN14770 is a highly selective inhibitor of PDE4D, which regulates brain signaling pathways involved in the early and late stages of memory formation.